Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients With Recurrent Glioblastoma

Next Previous
X
Search
Trial Profile

A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients With Recurrent Glioblastoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NMS 293 (Primary) ; Temozolomide (Primary) ; Lomustine
  • Indications Astrocytoma; Glioblastoma; Oligodendroglioma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Nerviano Medical Sciences

    • Most Recent Events

    • 13 Mar 2024 Planned number of patients changed from 125 to 150.
    • 12 Oct 2023 Results (n=21) presented in a Nerviano Medical Sciences media release.
    • 12 Oct 2023 According to a Nerviano Medical Sciences media release, initial results data from this trial presented at the AACR-NCI-EORTC 2023 Annual Meeting in Boston, Massachusetts.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top